Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

at more than 160 sites in North America, Latin America, Europe and South Africa.

For more information about the VICTOR-E3 and VICTOR-E4 clinical studies, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

Status of Vicriviroc Phase II Study in Treatment-Naive Patients

Schering-Plough also has completed patient enrollment in the first part of an ongoing Phase II study of vicriviroc in a novel nucleoside-sparing regimen for first-line therapy of adult treatment-naive HIV-infected patients with R5-tropic virus only. Approximately 80-90 percent of treatment-naive patients have virus that uses the CCR5 co-receptor.(5) The study evaluates vicriviroc 30 mg once-daily in combination with ritonavir-boosted atazanavir,(6) compared to a control group receiving Truvada (emtricitabine and tenofovir disoproxil fumarate)(7) plus ritonavir-boosted atazanavir, which is a currently recommended option for first-line therapy. This novel nucleoside-sparing vicriviroc regimen is designed to help avoid the risk of toxicities associated with the nucleoside class of HIV drugs, which can include neuropathy, myopathy, renal toxicity, hepatic steatosis, lactic acidosis, bone marrow suppression, fat atrophy and, with certain agents, increased risk of myocardial infarction.(8-10) This approach represents a potential opportunity to preserve nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs), integrase inhibitors, fusion inhibitors and most protease inhibitors for later lines of HIV treatment. The full study will involve approximately 200 patients and is ongoing at more than 20 sites in North America, Central America, Europe and South Africa.

For more information about the study, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is an innov
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Research and Markets ( ... "North American Active Wound Care Market by ... & Ulcer), by End-User (In-Patient, & Out-Paient) - ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North ... grow at a CAGR of 3.1% from 2014 ...
(Date:5/21/2015)... REDWOOD CITY, Calif. , May 21, 2015  Cardica, ... 20, 2015, new employee Greg Watson , the company,s ... 400,000 shares of the company,s common stock, at a per ... May 20, 2015. The stock option was granted pursuant to ... board of directors in May 2015 under Rule 5653(c)(4) of ...
(Date:5/21/2015)... CAMBRIDGE, England , May 21, ... zur Bekämpfung von Arzneimittelfälschungen - Zwecks ... eines Arzneimittelprüfdienstes wird auf EG-Mitgliedstaaten verwiesen, ... Pilotsysteme betrieben werden.  Wählen Sie ein ... Bei der Richtlinie zur Bekämpfung von ...
Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... Technology advances have had a profound effect on ... a constantly evolving communication environment, companies need to continuously ... It is challenging, however, to gauge the effectiveness of ... of today,s internal and external communication options. ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at the 2011 Credit Suisse Annual ... live presentation takes place on Wednesday, November 9, 2011 at ... 1:00 p.m. Pacific Time.  The presentation will be webcast and ...
Cached Medicine Technology:Internal and External Communication Insights: Effective Approaches for Reaching Clients and Co-Workers 2
(Date:5/25/2015)... (PRWEB) May 25, 2015 A recent report ... states 1,000 persons have died as a direct result of ... This marks a 33% rise in overdose deaths attributed to ... Baker, “This issue doesn’t care about geography. This issue doesn’t ... issue doesn’t care about class.” As the state of Mass. ...
(Date:5/25/2015)... 2015 ProDrop Light Show allows users ... light backdrops with a click of a mouse. Users have full ... all within Final Cut Pro X. , ProDrop Light Show gives ... zones, kaleidoscope and much more leaving infinite possibilities all within Final ... zones and text presets, users can apply their very own media ...
(Date:5/25/2015)... Americas announces major investment in new technology and personnel ... Medical Answering Service customers. Through a combination of ... provides a seamless transition between a health care provider’s ... patient satisfaction. , Tunstall is pleased to ... expanded facilities and the latest telecommunication software and hardware ...
(Date:5/24/2015)... (PRWEB) May 25, 2015 Pacific Prime has announced ... part report looking at the cost of individual international health ... Article 2 looks at the cost of health insurance in six ... Focusing on, Hong Kong , ... the UAE , the UK , ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 For people ... and Chinese Enterokinase Industry, 2009-2019 Market Research Report would ... is an exhaustive study on the present market scenario ... insight into the growing Chinese market of this industry. ... the overall status of the manufacturers in this industry. ...
Breaking Medicine News(10 mins):Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4
... Choices ( http://www.nhs.uk ), the,digital ,front door, to the ... to see both the physical and financial cost of ... information, the interactive calculator,( http://www.nhs.uk/Tools/Pages/Smoking.aspx ) enables users to ... up how much you could save over,one to ten ...
... 11 In this 90 minute episode, Dr. Drew,reunites several ... they left treatment. Drew reveals who has relapsed, who has ... is comprised of,recovering addicts and fans of the show, will ... happened over the season., (Photos: ...
... suggests eating foods such as whole grains cuts risk ... -- Increased consumption of magnesium-rich foods such as whole ... which occurs when blood flow to the brain is ... the Karolinska Institute in Stockholm analyzed the diets and ...
... ALLEGAN, Mich., March 11 Perrigo Company,(Nasdaq: ... final approval,from the U.S. Food and Drug Administration (FDA) ... Foam, 0.05%., The product is a topical corticosteroid ... the scalp. Sales for the brand, Olux(R),Foam, 0.05%, were ...
... Verathon(R) is pleased to,announce a new Small Child ... instrument with patent-pending NeuralHarmonics(TM),Technology. Small Child Mode enables ... children weighing less than 60 pounds and,standing less ... used for adult,patients. This enhanced BladderScan(R) BVI 9400 ...
... . , Malignant tumors have usually lost their ... apoptosis. Therefore, tumors are often resistant to chemotherapy or ... cells to commit suicide. , This resistance to ... numerous molecular switches regulating the self-destruction process. This is ...
Cached Medicine News:Health News:Magnesium May Lower Risk for Some Strokes in Male Smokers 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 3Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 2Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 3Health News:Paradigm shift: Switch for programmed cell death promotes spread of glioblastoma 2
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... catheter or instrument introduction. The dual ... peeled away and removed. The maximum ... to be introduced should be measured ... sheath. Supplied sterile in peel-open packages. ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: